

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Regenerative Medicine International Limited**  
**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

**INSIDE INFORMATION**  
**DELAY IN PUBLICATION OF 2022 ANNUAL RESULTS AND**  
**DELAY IN DESPATCH OF ANNUAL REPORT**  
**AND**  
**SUSPENSION OF TRADING**

This announcement is made by China Regenerative Medicine International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 21 March 2023 (the “**Announcement**”), in relation to, among other things, the date of Board meeting for the purpose of considering and approving the audited annual results of the Group for the year ended 31 December 2022 and its publication thereof, and considering the recommendation for payment of a final dividend, if any (the “**Board Meeting**”). Unless otherwise defined, any capitalized terms used herein shall have the same meanings as those used in the Announcement.

## **DELAY IN PUBLICATION OF ANNUAL RESULTS AND DELAY IN DESPATCH OF ANNUAL REPORT**

Pursuant to Rules 18.03, 18.48A, 18.49 and 18.50C of the GEM Listing Rules, the Company is required (i) to publish the preliminary announcement of the annual results for the year ended 31 December 2022 (the “**2022 Annual Results**”), which is agreed with the auditor of the Company (the “**Auditor**”); and (ii) to despatch the annual report for the same financial year (the “**2022 Annual Report**”) to the shareholders of the Company (the “**Shareholders**”), on a date not later than three months after the end of the financial year of the Company, i.e. 31 March 2023.

Accordingly, the Board Meeting was convened on 31 March 2023 at the scheduled time. The Board wishes to inform the Shareholders and potential investors of the Company that the preparation for the 2022 Annual Results has been delayed due to the delay in the audit work as the Auditor is still collecting information necessary for performing its audit work and certain confirmations from external parties are yet to be collected. As such, the Auditor requires more time for conducting the audit of the 2022 Annual Results and the Company is not able to publish the audited 2022 Annual Results on or before 31 March 2023.

The Board acknowledges that any delay in publishing the 2022 Annual Results and the despatch of the 2022 Annual Report will constitute non-compliance with Rules 18.03 and 18.49 of the GEM Listing Rules. The Company will use its best endeavours to publish the 2022 Annual Results and despatch the 2022 Annual Report to the Shareholders as soon as possible. It is expected that the 2022 Annual Results will be published and 2022 Annual Report will be despatched on or before 14 April 2023.

## **SUSPENSION OF TRADING**

Pursuant to Rule 17.49A of the GEM Listing Rules, the Stock Exchange will normally require suspension of trading in the Company’s securities if the Company fails to publish periodic financial information in accordance with the GEM Listing Rules, and the suspension will normally remain in force until the Company publishes an announcement containing the requisite financial information.

Therefore, trading in the shares of the Company is currently expected to be suspended with effect from 9:00 a.m. on 3 April 2023, pending the publication of 2022 Annual Results and the despatch of the 2022 Annual Report by the Company.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board

**China Regenerative Medicine International Limited**

**Wang Chuang**

*Chairman, Chief Executive Officer and Executive Director*

Hong Kong, 31 March 2023

*As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Mr. Tsang Ho Yin; and the independent non-executive Directors are Ms. Huo Chunyu, Dr. Liu Ming and Mr. Leung Man Fai.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of its publication. This announcement will also be published on the Company’s website at [www.crmi.hk](http://www.crmi.hk).*